-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The current prognosis of advanced gastroesophageal cancer (GEC) is very poor, and the treatment options available are limited.
immunity
At present, several immunotherapy biomarkers have been verified to be used in the clinical treatment of GEC, including the expression of programmed death ligand-1 (PD-L1), and broad-spectrum biomarkers independent of tumor type, such as mismatches Repair or microsatellite instability (MMR/MSI) and tumor mutational burden (TMB).
In addition to tumor type-independent markers MSI and TMB, the only validated predictive biomarker for immunotherapy in GEC is PD-L1 CPS.
In the future, it is important to determine the role of immunotherapy biomarkers in combination therapy, especially when immunotherapy is used together with therapies with other mechanisms of action, whether a biomarker can maintain its predictive power.
Original source:
Robin Park, et al.
ncbi.
nlm.
nih.
gov/33916348/" target="_blank" rel="noopener">Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer : MSI and Beyond
in this message